Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	1.75T +34.1%
Revenue (ttm)	1.57T +10.4%
Net Income	195.86B +691.8%
EPS	17,021.64 +691.8%
Shares Out	11.51M
PE Ratio	8.92
Forward PE	10.54
Dividend	600.00 (0.40%)
Ex-Dividend Date	Dec 29, 2025

Volume	26,530
Average Volume	31,641
Open	150,000
Previous Close	149,600
Day's Range	148,800 - 152,600
52-Week Range	128,400 - 199,400
Beta	0.16
RSI	46.12
Earnings Date	May 15, 2026

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,644
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2025, Daewoong Pharmaceutical's revenue was 1.57 trillion, an increase of 10.42% compared to the previous year's 1.42 trillion. Earnings were 195.86 billion, an increase of 691.83%.